Gilead touts speedier-than-expected pipeline advances amid solid Q2 drug sales, except Covid-19 treatment Veklury

Beth Snyder Bulik

Senior Editor

The key qualifying phrase to Gilead Sciences’ solid second quarter earnings was “excluding Veklury.” That’s because the Covid-19 treatment was the spoiler dropoff in a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Gilead touts speedier-than-expected pipeline advances amid solid Q2 drug sales, except Covid-19 treatment Veklury

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

Gilead touts speed­i­er-than-ex­pect­ed pipeline ad­vances amid sol­id Q2 drug sales, ex­cept Covid-19 treat­ment Vek­lury

Senior Editor

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Gilead touts speedier-than-expected pipeline advances amid solid Q2 drug sales, except Covid-19 treatment Veklury